Agoracom Blog

Mota Ventures $MOTA.ca Announces 832% Growth in February 2020 over the Same Period Last Year and Provides Update on First Class CBD Sales $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 5:33 PM on Friday, March 13th, 2020
http://www.smallcapepicenter.com/Mota%20Square%20Logo%20For%20Blog.jpg

VANCOUVER, BC / March 13, 2020 / Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ1)(OTC:PEMTF) (the “Company“) is excited to announce that for the month of February 2020, its First Class CBD brand achieved sales of Cdn$2,981,000, with related expenses for the same time period totaling Cdn$2,814,000. Due to accelerated marketing efforts in late January 2020, the brand was able to improve gross margins by 4.9% from January 2020 to February 2020. The Company anticipates these efforts will yield a further positive impact on revenue and margin in subsequent months. Sales for February 2019 were Cdn$320,000; therefore, February 2020 represents an increase of 832% over the same period last year.

First Class offers a CBD hemp-oil formulation intended to provide users with the therapeutic benefits that hemp may offer. The hemp oil used in the products is derived from hemp grown and cultivated in the United States. The extraction process is designed to maintain all the beneficial qualities that hemp may offer. First Class offers a range of products, which include CBD oil drops, CBD gummies, CBD pain relief cream, CBD skin serum and CBD coffee. The Company plans to continue growth of First Class in the United States over the balance of 2020, as well as an expansion into the European market.

“I am extremely pleased with the performance of the First Class brand through the beginning months of 2020. The continued growth we are experiencing is evidence of the strong consumer demand in the CBD market. While eCommerce demand is generally weakest in January and February, we continue to demonstrate our leadership through achieving approximately Cdn$5,874,000 in revenue through the first two months of the year,” stated Ryan Hoggan, CEO of the Company.

The Company cautions that figures for revenue, expenses and margin generated from the sale of First Class CBD products have not been audited, and are based on calculations prepared by management. Actual results may differ from those reported in this release once these figures have been audited. These figures were translated from US dollar into Canadian dollar using the Bank of Canada monthly average exchange rates of 1.3301 for January 2019, 1.3206 for February 2019, 1.3087 for January 2020 and 1.3286 for February 2020.

About Mota Ventures Corp.

Mota Ventures is seeking to become a vertically integrated global CBD brand. Its plan is to cultivate and extract CBD into high-quality value added products from its Latin American operations and distribute it both domestically and internationally. Mota has established distribution networks through the acquisition of First Class CBD in the United States and Sativida in Europe. Mota Ventures is also seeking to acquire revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Empower Clinics $CBDT.ca – #Cannabis Won’t Cure #Coronavirus, but It Can Help Ease Certain Flu Symptoms $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $OGI.ca

Posted by AGORACOM-JC at 5:00 PM on Friday, March 13th, 2020

SPONSOR:

Why Empower Clinics

  • A leading owner/operator of physician staffed health and pain management clinics.
  • Patient database of over 165,000 patients 
  • Platform generating $1.4M USD (9 months ending Sept. 30, 2019)
  • Proprietary technology platforms including Electronic Health Records portal and e-Commerce for CBD product distribution
  • Recently launched CBD extraction facility
  • First extraction system capacity = 2,300 Kg per year.
  • CBD based products are poised to be a $20B global industry by 2022
  • Medical cannabis is poised to be a $100B global industry by 2025
  • Company to Create Psilocybin and Psychadelics Division Leveraging Corporate Wellness Clinics and Franchise Clinic Network

Cannabis Won’t Cure Coronavirus, but It Can Help Ease Certain Flu Symptoms

By Brianna Wheeler |

During a normal flu season, frequent weed smokers know the drill.

Pay closer attention to everyone’s cough patterns during a smoke sesh. Stop accepting mouth-wet blunts from strangers. And if you think you’re coming down with something, wave a lighter under the mouthpiece before passing the pipe.

This year, obviously, things are a bit more serious. We’re dealing with multiple citywide quarantines, global economic disruption, and a pandemic being compared to the damn Spanish flu. It’s enough to make self-respecting cannabis enthusiasts re-evaluate their medicine cabinet and diversify their stash box.

Obviously, there’s no dependable research on CBD’s or THC’s effect on COVID-19. But we do know a few things about cannabis and general wellness. Down the rabbit hole of alternative cannabinoids and non-psychoactive cannabis, there is a wealth of potential medicinal benefits both preventative and curative.

At least when it comes to the regular flu, CBD has been found to help support immune systems, ease symptoms, and replace over-the-counter pain relievers, sleep aids, and medicated salves currently taking up space in our medicine cabinet. But not just any CBD will do, and CBD alone won’t do it all.

Obviously, the best course of action right now is to keep vigorously washing your hands, mind your coughs, avoid large crowds, and be a bit more stingy with your pipes and joints. But if you find yourself slipping under the weather, for whatever reason, here are a few things to know about how cannabis might help ease symptoms.

CBD for Immune System Support

Tons more research is required to accurately map the relationship between the immune and endocannabinoid systems, but it’s well established that CBD helps reduce self-harming autoimmune and inflammatory responses. “CBD has been found to act as an immune system modulator,” says Anna Symonds, director of East Fork Cultivars’ CBD Certified program. “This means that it’s like a thermostat—it can turn the level of activity down or up, depending on the body’s needs.”

Source: https://www.wweek.com/potlander/2020/03/10/cannabis-wont-cure-coronavirus-but-it-can-help-ease-certain-flu-symptoms/

How Swiss scientists are trying to spot #deepfakes – SPONSOR: Datametrex AI Limited $DM.ca

Posted by AGORACOM-JC at 4:13 PM on Friday, March 13th, 2020

SPONSOR: Datametrex AI Limited (TSX-V: DM) A revenue generating small cap A.I. company that NATO and Canadian Defence are using to fight fake news & social media threats. The company announced three $1M contacts in Q3-2019. Click here for more info.

How Swiss scientists are trying to spot deepfakes

By Geraldine Wong Sak Hoi

As videos faked using artificial intelligence grow increasingly sophisticated, experts in Switzerland are re-evaluating the risks its malicious use poses to society – and finding innovative ways to stop the perpetrators.

In a computer lab on the vast campus of the Swiss Federal Institute of Technology Lausanne (EPFL), a small team of engineers is contemplating the image of a smiling, bespectacled man boasting a rosy complexion and dark curls.

“Yes, that’s a good one,” says lead researcher Touradj Ebrahimi, who bears a passing resemblance to the man on the screen. The team has expertly manipulated Ebrahimi’s head shot with an online image of Tesla founder Elon Musk to create a deepfake – a digital image or video fabricated through artificial intelligence.

It’s one of many fake illustrations – some more realistic than others – that Ebrahimi’s teamexternal link has created as they develop software, together with cyber security firm Quantum Integrityexternal link (QI), which can detect doctored images, including deepfakes.

Using machine learning, the same process behind the creation of deepfakes, the software is learning to tell the difference between the genuine and the forged: a “creator” feeds it fake images, which a “detector” then tries to find.

“With lots of training, machines can help to detect forgery the same way a human would,” explains Ebrahimi. “The more it’s used, the better it becomes.”

Forged photos and videos have existed since the advent of multimedia. But AI techniques have only recently allowed forgers to alter faces in a video or make it appear the person is saying something they never did. Over the last few years, deepfake technology has spread faster than most experts anticipated.

The team at EPFL have created the image in the centre by using deep learning techniques to alter the headshot of Ebrahimi (right) and a low-resolution image of Elon Musk in profile found on the Internet.​​​​​​​ (EPFL/MMSPG/swissinfo)

The fabrication of deepfake videos has become “exponentially quicker, easier and cheaper” thanks to the distribution of user-friendly software tools and paid-for services online, according to the International Risk Governance Center (IRGC)external link at EPFL.

“Precisely because it is moving so fast, we need to map where this could go – what sectors, groups and countries might be affected,” says its deputy director, Aengus Collins.

Although much of the problem with malign deepfakes involves their use in pornography, there is growing urgency to prepare for cases in which the same techniques are used to manipulate public opinion.

A fast-moving field

When Ebrahimi first began working with QI on detection software three years ago, deepfakes were not on the radar of most researchers. At the time, QI’s clients were concerned about doctored pictures of accidents used in fraudulent car and home insurance claims. By 2019, however, deepfakes had developed a level of sophistication that the project decided to dedicate much more time to the issue.

“I am surprised, as I didn’t think [the technology] would move so fast,” says Anthony Sahakian, QI chief executive.

Sahakian has seen firsthand just how far deepfake techniques have come to achieve realistic results, most recently the swapping of faces on a passport photo that manages to leave all the document seals intact.

Read More: https://www.swissinfo.ch/eng/sci-tech/manipulated-media_how-swiss-scientists-are-trying-to-spot-deepfakes/45595336

CLIENT FEATURE: Vertical Exploration $VERT.ca Partners with AREV Brands to Distribute Wollastonite to the Cannabis and Hemp Industries $TORR.ca $FA.ca $WEED.ca $CGC $ACB $APH $CRON.ca $HEXO.ca $TRST.ca $OGI.ca

Posted by AGORACOM at 11:13 PM on Thursday, March 12th, 2020

Vertical Exploration is developing its St. Onge Wollastonite as a soil additive for optimizing marijuana growth. Recently engaged AGRINOVA’s Phase 1 Reseach program also demonstrated Wollastonite can potentially become BNQ certified for agricultural use in Quebec. Recently signed distribution agreement with AREV Brands International to Supply St-Onge Wollastonite to the Cannabis and Hemp Industries. Click Here for More Info.

  • Definitive distribution agreement to partner on the sale of Vertical’s wollastonite from its world-class St-Onge Deposit in place.
  • Supplying the fast growing cannabis and hemp industries.
  • Vertical’s high quality Wollastonite has been shown to be beneficial to cannabis plants in a variety of ways
  • In every case the most optimal results occurred with an admixture rate of 10% to 15% wollastonite to the growth medium.
  • The high-grade St-Onge Wollastonite deposit has pit-constrained mineral resources of: 7,155,000 tonnes Measured@ 36.20% Wollastonite & 6,926,000 tonnes Indicated@ 37.04%
  • B.C. Buds Testing Confirmed Wollastonite is critical to marijuana growers
  • Engaged AGRINOVA over the past year to conduct research and testing of Vertical’s St-Onge wollastonite on a range of important agricultural end uses.

WOLLASTONITE

  • St-Onge-Wollastonite Deposit located approximately 90 kilometres Northwest of the city of Saguenay, in St-Onge township, in the Saguenay-Lac-St-Jean region of Quebec, Canada.
  • Wollastonite is a calcium inosilicate mineral that may contain small amounts of ironmagnesium, and manganese substituting for calcium
  • Research and testing in the Phase 1 program for use in cannabis growth was managed and monitored by AGRINOVA, a highly-regarded Center for Research and Innovation in Agriculture in Quebec

St-Onge-Wollastonite Deposit:

HUB on Agoracom

FULL DISCLOSURE: Vertical Exploration is an advertising client of AGORA Internet Relations Corp.

#Coronavirus Scare Gives #Telehealth an Opening to Redefine Healthcare #Mhealth SPONSOR: CardioComm Solutions $EKG.ca – $ATE.ca $TLT.ca $OGI.ca $ACST.ca $IPA.ca

Posted by AGORACOM-JC at 6:12 PM on Thursday, March 12th, 2020

SPONSOR: CardioComm Solutions (EKG: TSX-V) – The heartbeat of cardiovascular medicine and telemedicine. Patented systems enable medical professionals, patients, and other healthcare professionals, clinics, hospitals and call centres to access and manage patient information in a secure and reliable environment.

Coronavirus Scare Gives Telehealth an Opening to Redefine Healthcare

With the coronavirus threatening to become a pandemic, health systems and telehealth vendors see this as an opportunity to bring connected health to the forefront – and reshape the future of healthcare.

By Eric Wicklund

March 05, 2020 – As Congress votes on a funding package that includes Medicare waivers for some telehealth services and the Health Information and Management Systems Society (HIMSS) cancels its conference in Florida, healthcare providers across the country are looking at how connected care programs can be used to handle the coronavirus – also called COVID-19 – threat.

Most see the exercise as an extension of their preparations for flu season. Some see this as an opportunity to lobby for telehealth adoption across the board, saying a possible epidemic offers ample evidence of the value of telehealth and mHealth.

Defining Telehealth’s Value in a Changing Landscape

“COVID-19 is different because we do not know all the factors surrounding transmission and its effects on patients,” Jason Hallock, Chief Medical Officer for SOC Telemed, points out. â€œBecause coronavirus is new and there have been a significant number of deaths, the uncertainty surrounding that is scaring both patients and the general public. Our healthcare workers do not have all the answers yet. Telehealth providers are challenged to make recommendations when there are still many unknowns. Telemedicine can be useful to evaluate and reassure patients in alternative settings, and also can be used to help patients decide who needs to be seen in the hospital or an alternative setting like an urgent care.”

Hallock says telehealth can help by enabling healthcare providers to treat isolated patients, thus preventing the spread of what has so far been an extremely contagious virus.

In a Q&A with mHealthIntelligence, Peter Antall, MD, President and Chief Medical Officer for American Well, offered an in-depth take on how telehealth might be used.

READ MORE: Scripps Researchers Use mHealth Wearables to Track Flu Outbreaks

Q. Telehealth has long been seen as an ideal means of expediting care during flu outbreaks. How is the coronavirus scare different? Does this pose any unique challenges that telehealth can address?

A. The novel coronavirus, or COVID-19, is similar to influenza in how it is transmitted (airborne), how symptoms manifest themselves, and the fear it stirs among those individuals at risk. When evaluating patients through telehealth, we use similar methodology as that used for influenza, except that the current Centers for Disease Control and Prevention (CDC) recommendations call for risk stratification based on known exposure or travel to endemic areas and referral for testing for those at high risk or those who are sick enough to need hospital care. Also, unlike with influenza, there are no current specific treatments, like antivirals, for the coronavirus at this time. 

If local person-to-person spread expands to wide community spread, we expect care will need to evolve to a method that is quite similar to how we treat influenza today. Under those circumstances, we will likely begin diagnosing coronavirus-like illness (CLI) on a clinical basis, without testing. We would likely then only be expected to refer inpatients with CLI who need hospital care clinically, while those with milder symptoms will likely be treated and monitored at home so as to limit the spread of this disease and not overwhelm our healthcare facilities.

In this way, telehealth is an ideal venue for an outbreak like this. We can increase access to care. We can offer care that is commensurate with the acuity and nature of the symptoms and make referrals as needed. This helps with infection prevention and control and also allows patients to receive their care in the home without exposing themselves to further illness.

One other notable point is the potential for telehealth to help in providing routine care for other conditions and offset coronavirus fears in the . Patients have other healthcare needs unrelated to coronavirus, but many are afraid to go to healthcare settings for fear of catching disease. This has begun to result in a migration of patients to telehealth. For example, on February 25, we saw telehealth urgent care patient volume that was 11 percent higher than expected. Many patients are now sharing anecdotes indicating they were afraid to sit in a waiting room, so they used telehealth instead.

READ MORE: Using Telehealth Technology for Care Coordination During a Disaster

Q. Are there new tools or technologies available that can be useful in dealing with the coronavirus?

A. Telehealth itself is a tool in this fight. Keep in mind that there are many varieties of telehealth. It can be used to connect a doctor or other provider with a patient in the home via smartphones or tablets. It can also be used for provider (specialist)-to-provider consultations in remote areas, for example. Telehealth carts also exist in healthcare settings and can be used not only to import care, but also to limit healthcare workers’ exposure to the virus by using a cart in the isolation room.  We see patients primarily through live video interactions, but we also can fall back to informed telephone calls, synchronous chatting for therapy and asynchronous secure messaging for ongoing communications.

The use of symptom trackers and chatbots is another promising area for coronavirus response. These technologies allow algorithms to be created and adjusted as more is learned about the coronavirus. These bots interact with patients and can perform assessments, triage and ongoing support. The bots can even escalate an interaction to a telehealth encounter or refer the patient for in-person care.

Finally, home monitoring and medical tricorders are another promising approach to care. Traditional remote patient monitoring has established value for managing certain chronic conditions, but the next wave of home monitoring includes consumer devices like smartwatches (like the Apple Heart Study), home TVs, and home medical tricorders like Tytocare that can perform a remote examination. These tools aid clinicians and patients and provide more robust health data conveniently from the home setting. Providers can also use the data generated to better care for the patient or regularly monitor certain conditions.

Q. What must care providers know about telehealth before using it to deal with the coronavirus?

READ MORE: HHS Is Looking For mHealth Devices That Can Diagnose Influenza

A. Providers must know and understand their role in this or any other healthcare crisis. They should be well informed and trained to follow current CDC or World Health Organization guidelines. They should also understand that telehealth is a powerful tool for helping fight this outbreak. And they should know that telehealth is a safe way to treat and/or triage these patients. Whether the provider is a primary telehealth provider or is not using telehealth today, there is a real opportunity to participate and play a role in the response. 

Providers who have a brick-and-mortar practice should be encouraged to use telehealth as a triage tool. Providers also need to understand that during this time, patients with other non-respiratory conditions also need care. These patients should be afforded a safe way to access care without risk of infection. Telehealth is also a tool to aid in this process, as some patients are fearful of going to healthcare facilities right now. The office-based provider can likewise process other patients by practicing this way.

Q. What are the barriers or challenges associated with using telehealth to deal with the coronavirus scare?

A. Telehealth visits are typically sufficient to complete a robust initial assessment. This allow the provider to assign a risk category, make other diagnoses, or deem the patient as “worried well.” Some patients may require additional care, as most telehealth in the home lacks certain medical peripherals that might be needed. Other reasons for referral would include a high-risk patient who needs to be tested or a patient who requires escalation of care due to the severity of their illness. Telehealth visits are generally sufficient for screening patients, assigning a risk category, answering questions and recommending the next steps a patient should take.

The barriers to telehealth—such as instances when the patient and provider do not yet have a relationship—are easily overcome providers receive similar training around the use of telehealth and as longitudinal patient records become more available to guide care. Occasionally the lack of medical peripherals or the inability to touch the patient during an exam is a barrier, as some patients need hands on care (e.g., IV, procedures). We have policies that mitigate these problems in most cases. However, on occasion, a telehealth patient must be referred for in-person evaluation.

Q. Is there anything that the CDC or any other government agency can do to support telehealth adoption to deal with the coronavirus? 

A. It is useful for the CDC (and the WHO) to highlight the important role of telehealth in this outbreak because it certifies our role within the broader medical community and raises awareness about this tool.

It would be helpful if the CDC were to make specific recommendations to telehealth providers that relate to telehealth evaluation of the coronavirus and associated referrals, coding and monitoring. It would also be helpful if the CDC were to play a role in advocacy efforts focused on government reimbursement, particularly in this emergency situation. Efforts to increase consumer awareness about telehealth as a safe option for care also could prove essential. When this outbreak settles down, we would encourage the CDC and HHS to collaborate around coronavirus standards of care and preparedness so that patients can expect telehealth providers to be ideally prepared and well-coordinated for the next outbreak and so that we can offer high-quality care in this manner to all Americans.

We also believe that our public health system would benefit greatly from owning its own telehealth network infrastructure. This would allow the CDC to better scale up, solve for geography and improve surveillance. It would even allow its public health workers to use technology to monitor patients under quarantine in the home, saving themselves travel and limiting healthcare workers’ exposure.

Q.  What more can be done with telehealth in the future to plan for these types of outbreaks, or to perhaps address them before they become serious?

A. Much needs to be done throughout our country to better prepare. We need permanent leaders placed at the U.S. Department of Health and Human Services, the National Institutes for Health, the US Department of Homeland Security and other key areas, and we need to reinstate a pandemic-preparedness role at the National Security Council. We need to fund international efforts to improve screening and research for emerging diseases, and we need surveillance programs and good international coordination. We need to fund (not decrease funding) for our frontline groups, like the CDC, HHS and local public health services. These are our fighters, and we need them ready and funded properly as an outbreak like this is a national security issue. We need stockpiles of materials. Finally, we should be partnering with the pharmaceutical industry on affordable medications and vaccine research.

Our national telehealth operation today acts like an emergency alert system. We see cases or potential cases before they are reported. At American Well, our influenza activity indicator map is more accurate and more timely than that of the CDC. We already play a meaningful role in many disease states, including outbreaks. There are still many adoption and awareness challenges that exist when it comes to telehealth. Hopefully this unfortunate event will help consumers, providers and others start to more clearly see how they can and should use telehealth for future healthcare needs.

Another barrier that we continue to work on is that of reimbursement. Telehealth is a cost-effective way of receiving care, but it is still not always a covered benefit by insurance. Most commercial plans are reimbursing and there is increasing adoption in Medicare Advantage and Medicaid managed care. But there are still gaps, including a big gap in fee-for-service coverage for Medicare coverage in the home. Efforts at reform are underway (see the CONNECT Act), but more work needs to be done so that all Americans can take advantage of this amazing service.

Additionally, with coordination being so important during outbreaks like this, the simple step of integrating telehealth with other health information systems, such as EHRs or clinical-decision support, can make care more seamless and foster better care coordination. This would speed up access to critical care. Case in point: Consider a scenario where a patient consults with a physician over a telehealth network and displays symptoms of COVID-19 while presenting one or more correlating risk factors. The physician could easily document the experience, dispatch an alert to a local ED, and ensure precautions are taken by medical staff to usher this patient into a contained room or unit to begin testing and treatment. We’re working to ensure this type of communication is happening at all levels, but there’s still much room for improvement on this front. 

Health System Execs Respond to the Threat

In an op-ed prepared for the Alliance for Connected Care, Todd J. Vento, MD, MPH, Intermountain Healthcare’s Medical Director of Infectious Diseases Telehealth Service; Ethan Booker, MD, Medical Director of MedStar’s Telehealth Innovation Center; and Lawrence “Rusty” Hofmann, MD, Stanford Health’s Medical Director of Digital Health, made their pitch for telehealth:

“Telehealth, which has proven to be a very useful tool in addressing patient needs during flu season, will improve our collective ability to address COVID-19 if it hits on a larger scale. Telehealth offers several advantages over in-person care in the event of a pandemic.

One key advantage of telehealth is speed,” the three wrote. “Patients can access clinicians 24/7 without an appointment or physical trip to the doctor. Using telehealth, our providers in the Stanford Primary Care team, MedStar Health and Intermountain Healthcare have been actively evaluating and treating patients with influenza.  Current providers at Stanford Health estimate that almost 50% of patients are getting oseltamivir (Tamiflu).  Because there is no current, specific medication for Coronavirus, we must be able to advise patients of reasonable self-directed treatment and surveillance to keep them home. 

Keeping patients at home is a significant advantage of telehealth. In-home video visits limit community exposure by allowing patients to avoid contact with other patients in waiting rooms and direct contact with providers during the exam.  Our health systems have providers who are equipped to work from their own homes, significantly increasing the safety of providers and bolstering the workforce to respond to crisis.  Workforce readiness in a crisis that may include such dramatic measures as school and day care closures is a significant concern for health systems which may be strained to respond.  Health systems are also using telehealth to continue surveillance of patients already identified as at risk while keeping them at home.

Next, telehealth ensures that treatment in brick-and-mortar settings is reserved for high-need patients.  Moreover, with patients being seen in their own homes, providers and health systems will be able to triage and screen exponentially more patients with telehealth vs. an in-person visit.

Finally, telehealth allows patients who do not have access to infectious diseases (ID) specialists to access this specialized care from the small number of experts across the country. When Intermountain first offered ID telehealth consultation to rural systems throughout the west, one provider fielded 1,000 consultation requests in the first fifteen months. To date, the service has provided telehealth care to over 4,700 patients, 50 percent of whom are over 65 years old.

Each of these advantages illustrate how telehealth can thwart the spread of COVID-19 and stop it from overwhelming our already stretched medical system.”

The three health executive also urged lawmakers to take action to reduce barriers to telehealth that have kept adoption low:

“Congress must act to ensure that seniors – a particularly vulnerable population generally and for this virus in particular – are able to receive necessary triage and care through telehealth. 

Today, there are restrictions in Medicare that prevent providers outside of very rural areas from being paid for care provided through telehealth. As a result, many providers do not offer telehealth services to seniors. The lack of reimbursement creates a perverse incentive of encouraging patients to come for in-person care, which will only overwhelm our health system as well as augment the virus’s spread.

Congress must give the Secretary of Health and Human Services the ability to waive these restrictions in times of public health emergencies. As part of the bipartisan, bicameral CONNECT for Health Act, telehealth champions in Congress foresaw this need and drafted a provision that would give the Secretary the ability to waive telehealth restrictions just as he/she would waive Conditions of Participation, Stark Laws licensure, or other requirements when public health emergencies are declared.”

Source: https://mhealthintelligence.com/news/coronavirus-scare-gives-telehealth-an-opening-to-redefine-healthcare

#Edtech firms offer free access to colleges that is impacted by #Coronavirus – SPONSOR: BetterU Education Corp. $BTRU.ca $ARCL $CPLA $BPI $FC.ca

Posted by AGORACOM-JC at 5:12 PM on Thursday, March 12th, 2020
SPONSOR:  BetterU Education Corp. aims to provide access to quality education from around the world. The company plans to bridge the prevailing gap in the education and job industry and enhance the lives of its prospective learners by developing an integrated ecosystem. Click here for more information.

Edtech firms offer free access to colleges that is impacted by Coronavirus

Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31

  • Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31.

By: Neha Alawadhi & Samreen Ahmad

Online education companies in India and globally are offering their paid programmmes to students — whether in school or pursuing higher education — free of cost because of the COVID-19 pandemic.

Beginning Thursday, online learning giant Coursera said it is going to provide every impacted university in the world free access to its course catalogue through ‘Coursera for Campus’ until July 31.

“We’re going to make ‘Coursera for Campus’ offering freely available to any college or university in the world that is impacted by coronavirus, in the hope that they can rapidly allow students to start learning and ensure we have minimal impact from coronavirus on the student community,” said Leah Belsky, chief enterprise officer and senior vice-president, Coursera.

Coursera, founded by Stanford Professors Andrew Ng and Daphne Koller, has 48 million registered learners worldwide and offers courses, specialisations, degrees, and certificate programmes online.

The ‘Coursera for Campus’ offers job-relevant online education to students, alumni, faculty, and employees of firms like Mindtree, Tata Communications, Axis Bank, Infosys, Airtel, and Manipal Group.

Indian universities can continue teaching their students online without creating new infrastructure. Coursera’s existing ‘Coursera for Campus’ partners include Manipal Academy of Higher Education, UPES, Shiv Nadar University, KL University, NMIMS, and Pearl Academy.

In India, it has 5 million registered learners, and is adding over 100,000 learners per month.

Universities can sign up to provide their enrolled students with access to more than 3,800 courses and 400 specialisations from Coursera’s top university and industry partners.

Similarly, Indian education technology firms are also offering free classes and course material for students impacted by the novel coronavirus. On Wednesday, the World Health Organization declared COVID-19 a global pandemic.

Edtech firm Byju’s also said it will provide free access to its complete app to school students till the end of April.

Some Indian states like Kerala, Karnataka and New Delhi have already announced the closure of schools.

A UNESCO report states that the education of over 290 million students across 13 countries will be interrupted because of the COVID-19 pandemic.

Another edtech platform Unacademy said it will conduct close to 20,000 free live classes on its platform, across exam categories like UPSC, banking, railways and so on.

Unacademy claims it has 10,000 educators, 13 million learners, and subscriptions for over 30 exam categories.

Educational Initiatives, a 20-year old edtech company based out of Bengaluru is also offering 60 days free access of Mindspark to all students, so that the school closure due to COVID-19 does not impact their learning.

Mindspark is an artificial intelligence-powered specialised mathematics programme developed for children’s learning.

Similarly, edtech firm Toppr is going to provide free live classes to students in classes 5 to 12.

While it is yet to be seen how effective these measures will be, Coursera’s Belsky said the US education system invested in digitising after events like Hurricane Katrina, which forced school and college students to miss studies for months.

According to some estimates, in New Orleans alone, 110 of the 126 public schools were completely destroyed and students had to be moved to neighbouring states to complete their education.

Source: https://www.business-standard.com/article/education/edtech-firms-offer-free-access-to-colleges-that-is-impacted-by-coronavirus-120031201574_1.html

2 of Top 5 CBD Consuming Countries in Europe SPONSOR: Mota Ventures $MOTA.ca $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM at 3:00 PM on Thursday, March 12th, 2020

SPONSOR: Mota is seeking to become a vertically integrated global CBD brand. Mota is looking to establish sales channels and a distribution network internationally through the acquisition of the Sativida and First Class CBD brands. Low cost production, coupled with international, direct to customer sales channels will provide the foundation for the success of Mota. Combined total sales of almost $29,000,000 with a EBITDA of approximately 12.5% (2019) . Click Here for More Info

Mota large
  • These countries are expected to account for virtually all of the legal marijuana sold globally in five years

Marijuana is one of the fastest growing industries on the planet. Legal weed sales have more than tripled between 2014 and 2018, and they’re on track to roughly quadruple between the $10.9 billion generated in licensed cannabis stores 2018 and the projected $40.6 billion in worldwide licensed store sales by 2024. That’s according to the 2019 “State of the Legal Cannabis Markets” report released earlier this year by Arcview Market Research and BDS Analytics.

Yet, what you might find intriguing about this rapid growth is that it’ll wind up being attributed to just a select few countries. Even though more than three dozen countries around the world have legalized medical marijuana, five countries are forecast by Arcview and BDS to account for $38.2 billion of this aforementioned $40.6 billion in licensed-store sales by 2024. Note, licensed-store sales doesn’t include general retailers selling cannabidiol (CBD) products, or cannabinoid-based drug developers selling pot-derived pharmaceuticals.

1. United States: $30.1 billion in cannabis spending by 2024

As should be no surprise, the U.S. projects as the leading marijuana market in the world by sales in 2024. In fact, the $30.1 billion in licensed-store revenue should comprise almost three-quarters of global licensed sales. According to Arcview and BDS, $9 billion of these sales are expected to come from the medical side of the equation, up from $4 billion in 2018, with the remaining $21.1 billion derived from recreational marijuana, up from $5.9 billion last year.

The thing about the U.S. is that cannabis stocks can still thrive even if the federal government doesn’t change its classification of marijuana from Schedule I. As long as Congress and the president continue to respect the right of states to make their own choices on cannabis, the industry could have plenty of runway.

One of the fastest early stage growers looks to be multistate dispensary operator Cresco Labs (OTC:CRLBF). Cresco, which holds the licenses to more than four dozen retail locations in 11 states, made a bold move in April when it announced an all-stock deal to acquire Origin House (OTC:ORHOF). Origin House is one of only a few companies to hold a cannabis distribution license in California, the state responsible for a quarter of all U.S. marijuana spending by 2024. Thus, Cresco Labs’ purchase of Origin House will give it access to more than 500 Californian dispensaries, and over 700 nationwide. Cresco and its vertically integrated peers appear well-positioned to take advantage of this huge growth opportunity.

2. Canada: $5.18 billion by 2024

Despite being the first industrialized country in the world to legalize recreational weed, Canada looks to take a distant second to the United States by 2024 in terms of sales. Arcview and BDS are projecting that $4.8 billion in sales will come from the recreational market by then, with the remainder made up of medical cannabis sales. It’s not uncommon for the medical industry to get cannibalized when adult-use marijuana is legalized, because it means patients no longer have to wait for a doctor’s approval and prescription to buy weed.

There’s a lot of competition in Canada right now, so it’s still unclear which company will be Canada’s kingpin. However, Aurora Cannabis (NYSE:ACB) is a relatively good bet to be near the top of the pack solely based on its production potential. Aurora is already leaps and bounds ahead of its next-closest competitors with an annual run-rate output of 150,000 kilos as of the end of March, and plans to be producing at least 625,000 kilos on a run-rate basis by the end of June 2020. With most of this production located in Canada, and the company sporting a number of large-scale grow farms, Aurora Cannabis should be able to take advantage of economies of scale to drive down its growing costs per gram.

Of course, the real near-term excitement revolves around the upcoming launch of derivative products (e.g,, edibles, vapes, topicals, concentrates, and infused beverages) by mid-December. Derivatives have much better margins and pricing power than dried cannabis flower, which is why Aurora Cannabis and its peers have been busy beefing up their product offerings over the past year in preparation for this upcoming launch date.

3. Germany: $1.35 billion by 2024

Even though Arcview and BDS are not expecting Germany to legalize recreational cannabis, the company’s highly permissive stance toward medical marijuana, and the fact that health insurers cover medical weed in the country, should allow sales to soar from $79 million in 2018 to $1.35 billion by 2024.

Interestingly enough, Canadian cannabis stocks were actually big-time winners of the German cultivation licensing process. Both Aurora Cannabis and Aphria (NYSE:APHA) were awarded licenses to grow cannabis in Germany. For its part, Aphria plans to have an 8,000-square-meter facility in Germany that’ll begin supplying the country with medical marijuana in the early part of 2020. In addition to growing cannabis, Aphria introduced CannRelief in Germany, which is a CBD-based nutraceutical and cosmetics product line. 

As for Aurora Cannabis, its approval to construct a growing facility will allow the company to supply the German market with 4,000 kilos of marijuana over four years, with shipments expected to commence October 2020. Of course, this production capacity is liable to be bumped up if patient demand merits it. 

4. Mexico: $1.02 billion by 2024

Arguably one of the oddest “legality” situations concerning marijuana right now is with Mexico. The nation’s Supreme Court has ruled five times since 2015 that imposing a ban on recreational cannabis is unconstitutional. That’s important, because when Mexico’s Supreme Court reaches five similar decisions on an issue, it becomes the standard throughout the country. Or, in layman’s terms, the Supreme Court has essentially affirmed the legality of recreational marijuana and is simply waiting for lawmakers in the country to hash out the details.

According to Arcview and BDS, Mexico will have legalized adult-use cannabis by 2024, although the ramp-up of legal sales could be slow. By 2024, recreational weed sales are only expected total $582 million, with an additional $441 million in medical spending, for a combined $1.02 billion. Mexico’s considerably larger population than Canada makes for an attractive market opportunity, but it’s unclear how well legal industries will fare with the noted presence of illicit producers.

One company that hasn’t been shy about its push into Mexico is Medical Marijuana, Inc. (OTC:MJNA), the very first publicly listed pot stock. Southern California-based Medical Marijuana was the first company to import CBD-rich oils into Mexico in 2016, giving it a head start on building important relationships with the country’s medical community. You’ll note that even with recreational legalization likely on the horizon, medical spending should continue to grow in Mexico. That gives Medical Marijuana and its RSHO-X hemp oil a real shot to continue penetrating the Mexico’s medical cannabis market. 

5. United Kingdom: $546.9 million by 2024

Although it may not be on track to tip the scales at $1 billion in sales by 2024, the U.K. is poised to be one of the fastest growing countries in the world based on cannabis spending. After only $9.9 million in medical spending last year, Britain is forecast for almost $547 million in medical marijuana revenue by 2024, representing a compound annual growth rate of 95.2%.

This sudden push to legalize and normalize medical pot use in the U.K. can be partially attributed to the success of GW Pharmaceuticals (NASDAQ:GWPH), the cannabinoid-based drug developer that had the U.S. Food and Drug Administration approve the very first cannabis-derived drug last year. GW Pharmaceuticals’ CBD-based oral solution known as Epidiolex dazzled in late-stage studies and wound up reducing seizure frequency for patients with two rare forms of childhood-onset epilepsy by 30% to 40%. Additionally, GW Pharmaceuticals’ Sativex, an oromucosal spray containing both CBD and tetrahydrocannabinol (THC), is approved in more than a dozen markets in Europe (but not the U.S.).

Britain’s citizens and its government have seen what the U.K.-based GW Pharmaceuticals can do with cannabinoids, and its government has been open to the possibility of expanding access to marijuana-based products for medical patients.

Sean Williams has no position in any of the stocks mentioned. The Motley Fool recommends Origin House. The Motley Fool has a disclosure policy.

SOURCE: https://www.fool.com/investing/2019/09/08/5-countries-with-the-highest-cannabis-spending-by.aspx

Why You Should Buy Gold Now! SPONSOR: Labrador Gold $LAB.ca $RIO.ca $WHM.ca $SIC.ca $NXS.ca

Posted by AGORACOM at 12:54 PM on Thursday, March 12th, 2020

SPONSOR: Labrador Gold – Two successful gold explorers lead the way in the Labrador gold rush targeting the under-explored gold potential of the province. Exploration has already outlined district scale gold on two projects, including a 40km strike length of the Florence Lake greenstone belt, one of two greenstone belts covered by the Hopedale Project. Recently acquired 14km of the potential extension of the new discovery by New Found Gold’s Queensway project to the south. Click Here for More Info

This image has an empty alt attribute; its file name is LAB-square-logo-2.png
  • Gold is known as the safe-haven asset, and whenever we see a meltdown in the equity markets or prospects of loose monetary policy, its price begins to explode to the upside.
  • Currently, the gold price has a strong negative correlation with the equity markets meaning when the equity markets fall; investors pour money into gold and vice versa.  
Gold and SPX chart shows negative correlation

The fact is that the current sell-off in the global equity markets is only a start because there is a lot more to come. After all, the economic weakness isn’t fully baked into economic data, let alone in earnings. Thus, there is no better time to buy gold.

Why?

First, the equity markets are in major turmoil as a 1000 point move for the Dow Jones index has become the norm. Secondly, the Coronavirus has pushed the Federal Reserve into a corner, and it’s being forced to keep its monetary policy on the dovish side. The Fed cut the interest rate by 50 basis points only a couple of weeks ago, and yet the market expects further cuts.

Gold which is up nearly 10% year-to-date is likely to score serious gain in the coming weeks. The reason is that we have a situation where monetary policy itself isn’t enough to calm the markets; however, governments are trying to provide support on the fiscal front as well. For instance, Donald Trump has pitched the idea of no payroll tax for this year to soften the blow of Coronavirus. So far, we have not seen a green flag which is why investors are still nervous. Donald Trump may achieve some of his goals, but it won’t be enough, the economic damage is too considerable, and the Coronavirus is still nowhere close to coming under control.

Going back to the monetary policy action and why there is serious potential for the gold price to increase; at present, traders and Wall Street are expecting further interest rate cuts from the Fed during their meeting next week. An interest rate cut of 50 basis points is the minimum that investors expect, and according to bigger banks like Goldman Sachs and JP Morgan, we can expect 75 basis points and a full percentage point.

Regarding the price action, an interest rate cut isn’t priced in at all, if it had been, the price would have been trading much higher. Currently, it’s trading near $1,661.

The Play

If the Fed cuts the interest rate by 50 basis points, this could push the gold price above 1700 again. Anything more than 50 basis points, especially a whole percentage point, could pump the price to 1750 or higher.

The Flow

If we look at the total gold ETF holding data, it supports our thesis that the gold price is likely to increase because the total holding in ETFs is sitting at a record level, and the inflow continues to rise. It appears that investors are discounting this current price weakness and using this opportunity to buy more.

The chart shows all gold ETFs holding at a record high level

 The Bottom Line

 The current retracement in the gold price is an enormous opportunity for traders to get back in the game or add to their position, similar to the institutions. If for some reason, the Fed doesn’t cut the interest rates during the meeting, it will create more panic in the equity markets, which would be a positive sign for the gold price.

SOURCE: https://www.forbes.com/sites/naeemaslam/2020/03/11/why-you-should-buy-gold-now/#7d3d34446828

Silver Has Almost Never Been This Cheap – But Should You Buy? SPONSOR: Affinity Metals $AAF.ca $SII.ca $TUD.ca $GTT.ca $AMK.ca $OSK.ca $RKR.ca

Posted by AGORACOM at 11:35 AM on Thursday, March 12th, 2020
This image has an empty alt attribute; its file name is Affinity_Metals_Corp_Logo.png

Sponsor: Affinity Metals Corp. (TSX-V: AFF) is a Canadian mineral exploration company building a strong portfolio of mineral projects in North America. The Corporation’s flagship property is the drill ready Regal Property near Revelstoke, BC where Affinity Metals is making preparations for a spring drill program to test two large Z-TEM anomalies. Click Here for More Info

  • With silver one hundred times cheaper than gold, the silver-gold-price ratio is close to an all-time high. The obvious trade is to sell gold and buy silver, says Dominic Frisby. But is that a wise move?
Silver’s value has plummeted since it stopped officially being money

A friend sent me a screenshot from his phone earlier in the week. It showed the gold price at $1,666/oz and silver at $16.66/oz. In other words an ounce of gold is 100 times the price of an ounce of silver. Or, to use the correct terminology, the gold-silver ratio has gone above 100 – which is almost unheard of.

According to my data, the gold-silver ratio has only ever gone above 100 once before. It didn’t happen in the financial crisis of 2008, the dotcom crash of 2000, or the Long Term Capital Management Fund Crisis of 1998. It happened in 1991. Silver was $3.50/oz at the time and gold was, of course, $350. (Actually, it was closer to $370 and the ratio touched 105).

Apart from 1991 the ratio has never been as high as it was on Monday. Not once in history. It’s one of the extraordinary extremes that the coronavirus panic has caused.

The obvious trade here is to sell gold and buy silver. But on the basis of ratios alone, you should also be selling gold and buying oil, base metals, stocks, just about anything. To be clear, now is not the time to be selling gold, particularly with all the fiscal stimulus that’s coming.

A gold-silver ratio of 15 is but a distant memory

The gold-silver ratio is an odd one. Really, it should be somewhere around 15. Silver is only 15 times as abundant as gold – there is about 15 times more silver in the earth’s crust as there is gold.

And, historically, the relative price of the two ranged between around 15 and 20. Until 1875 the USA was a bi-metallic standard – both silver and gold were money, in other words – and the exchange rate between the two metals was 15, more or less.

However, in the 20th century, as we all know, countries abandoned their ties to gold and silver and so money and metal went their separate ways. That ratio of 15 has become an ever-more distant memory.

It did hit 15 briefly in 1981 as the Hunt Brothers tried to corner the silver market. But this was an extraordinary situation. It wasn’t typical. The typical broader trend is that silver is losing its value relative to gold.

One day we will get back to 15, say the most diehard silver bugs. This was something I was convinced of in the ardent silver-fanatic days of my investment youth. I’m not so convinced today.

In fact, you could go one stage further. The gold-silver ratio should be lower than 15. Silver gets used, gold does not – all the gold that has ever been mined, pretty much, still exists somewhere. But silver, with its numerous industrial applications, gets consumed. The ratio between the two should be closer to ten. And yet here we are with that ratio ten times higher – and silver ten times too cheap.

The sad fact for silver bugs is that since silver no longer has any official monetary use, its relative value has plummeted. Some blame shenanigans on futures exchanges for the low price of silver – I blame the evolution of money.

Is the world going to go back to some sort of metallic standard as a result of coronavirus? I doubt it. Money is getting more and more digital; metal is too physical. But I can see one scenario where it might.

Get ready for epic debasement

The authorities’ reaction to the crisis will be to debase currency: slashing rates (we got a dose of that from the Bank of England just this morning), bailouts, money printing (which will be given some new name that is even more obfuscatory than quantitative easing), infrastructure spending (I gather the chancellor is to announce plenty of that in his Budget later today).

Gold bugs have long been waiting for that loss-of-faith moment when faith in fiat money will be lost. Might all the monetary manipulation that is already in place be the long-awaited trigger? The ensuing loss of faith sees us going back to metal.

It’s a possibility, I suppose, but I think I’m too long in the tooth to see that really happening.

I own some silver. I love silver. I don’t think it’s a bad thing to be holding in this time of crisis. If it wasn’t so “precious” it would have been dragged down a lot more – like energy and base metals. It’s certainly cheap. But so are a lot of other things at the moment.

The gold-silver ratio hit a low at 30 in 2011 when silver touched $50. It has been in an uptrend ever since. Plenty of us – me included – have tried to call the top in the ratio and it has kept grinding higher.

The likelihood is that it will pull back a little from the extremes, perhaps even as far as the 80s. But the reality of our modern fiat age is that, as far as the gold-silver ratio is concerned, it will take a fairly extreme change in circumstances for us even to get back to 50. 50 is the new 15.

Sell gold and buy silver as a trade, by all means, but make sure you reverse the trade – or at least start moving up the stops if we ever get back to the 80s, 70s or 60s.

SOURCE: https://moneyweek.com/investments/commodities/silver-and-other-precious-metals/600966/silver-has-almost-never-been-this

Bilayer Graphene Double Quantum Dots Tune in for Single-Electron Control SPONSOR – ZEN Graphene Solutions $ZEN.ca $LLG.ca $FMS.ca $NGC.ca $CVE.ca $DNI.ca

Posted by AGORACOM at 11:07 AM on Thursday, March 12th, 2020

SPONSOR: ZEN Graphene Solutions: An emerging advanced materials and graphene development company with a focus on new solutions using pure graphene and other two-dimensional materials. Our competitive advantage relies on the unique qualities of our multi-decade supply of precursor materials in the Albany Graphite Deposit. Independent labs in Japan, UK, Israel, USA and Canada confirm this. Click here for more information

The first demonstration of graphene double quantum dots in which it is possible to control the number of electrons down to zero has been reported in Nano Letters. Far from an abstract academic stunt, the results could prove key to future implementations of quantum computing based on graphene. “Having exact information and control over the number of electrons in the dots is essential for spin based quantum information technology,” says Luca Banszerus, a researcher at RWTH Aachen University in Germany and the first author of the paper reporting these results.

Although this level of control has been demonstrated in single quantum dots, this is the first demonstration in graphene double quantum dots, which are particularly useful as spin qubits. “Using a double dot heavily facilitates the readout of the electron’s spin state and the implementation of quantum gates,” Banszerus adds.

Less edgy quantum dots 

The idea of using graphene in quantum dots dates back almost as far as the first reports of the material’s isolation in 2004. Graphene has almost no spin-orbit interaction and very little hyperfine coupling, which would suggest that spin lifetimes can be extremely high. Unfortunately, quantum dots physically etched from larger graphene flakes run into problems due to the disorder at the dot’s edges disrupting the material’s behavior. As a result, the transport behavior of these quantum dots is dominated by localized states at the edges. “This leads to an unknown effective quantum dot size and an occupation of typically many electrons,” says Banszerus.

Instead, Banszerus and colleagues at RWTH Aachen and the National Institute of Materials Science in Japan work with bilayer graphene, which can be tuned to be a semiconductor. A voltage applied to specific regions of a bilayer graphene flake can switch those regions to behave as insulators, electrostatically defining a quantum dot that has no edge states nearby.

The Aachen researchers strip single flakes of bilayer graphene from graphite (mechanical exfoliation) and handle it using a dry pick-up technique that hinges on van der Waals interactions. They encapsulate the bilayer graphene in hexagonal boron nitride (hBN) crystal. They then place the structure on a graphite flake, which acts as the bottom electrode, and add chromium and gold split gates and finger gates separated from the split gates by a 30-nm-thick layer of atomic layer deposited Al2O3.

They were able to control the number of electrons on the quantum dots by applying a voltage, which also affected the tunneling coupling between the dots. As a result, once the total occupation of the two quantum dots exceeds eight electrons, they begin to behave as one single quantum dot, rather than a double quantum dot. Transport measurements also revealed that the number of electrons loaded on the quantum dot could be controlled down to zero electrons.

The idea of defining quantum dots in bilayer graphene electrostatically in this way is not new. However, although different groups have attempted this approach since 2010, the process required recently discovered tricks of the trade, such as better encapsulation in hBN and the use of graphite flakes as gates to get a clean band gap. Banszerus says these developments came as quite a surprise and revived interest in graphene quantum dots in 2018. He hopes the capabilities they have now demonstrated will further spark activity in this field.

Coupling control

“Even though being able to control the number of charges in a graphene double dot is a huge step forward, there are still many problems to be solved on the road toward spin-based quantum information technology in graphene,” says Banszerus. Next, he hopes to tackle the problem of controlling the coupling between the quantum dots and the reservoir, which he hopes to achieve by adding an additional layer of interdigitated finger gates on top.

Source: https://phys.org/news/2020-03-bilayer-graphene-quantum-dots-tune.html